RECOMBINANT VIRUS-LIKE PARTICLES (VLP) USING BOVINE IMMUNODEFICIENCY VIRUS GROUP-SPECIFIC ANTIGEN (GAG) PROTEIN Russian patent published in 2020 - IPC C12N7/01 A61K39/145 

FIELD: biotechnology.

SUBSTANCE: described is a virus-like particle (VLP) based on bovine immunodeficiency virus group (Bgag) group antigen protein containing one or more different target pathogen proteins. Disclosed is a vaccine comprising VGP Bgag according to claim 10. Disclosed is a transfer vector plasmid for producing VLP Bgag according to claim 1, which contains bovine immunodeficiency virus gag gene ("Bgag gene"), one or more genes from different target proteins-pathogens and one or more promoters. Described is a method of producing VLP Bgag according to claim 1, comprising the following steps: cloning into a plasmid a gene transfer vector Bgag and one or more genes from different target protein pathogens in tandem, wherein each is controlled by a promoter, preparation of a carrier virus using said transfer vector plasmid, infection of eukaryotic cells to create VLP Bgag and purification of the produced VLP Bgag. Described is a method for preventing or slowing down a disease caused by a target pathogen in animals, including a human, by administering an effective amount of the vaccine according to claim 13 to such animal. What is also described is a method for distinguishing patients who have been previously introduced with a vaccine according to claim 13, in which, whether the Bgag gene or the bovine immunodeficiency virus gag protein ("Bgag protein") is present in the patient, and the previous vaccination is correlated with the presence of the said Bgag gene or Bgag protein. Disclosed is VLP Bgag, containing one or more different nucleic acids, where nucleic acid induces or enhances the patient's immune response to the target object.

EFFECT: advantage of using virus-like particles of Bgag is possibility of distinguishing vaccinated subjects from unvaccinated.

20 cl, 41 dwg, 2 tbl, 21 ex